Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
NCT ID: NCT00823602
Last Updated: 2009-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
2 participants
INTERVENTIONAL
2008-03-31
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone antagonist in comparison with the standard long protocol in the first cycle of ART.
The investigators will randomize 160 patients undergoing ART for the first time . Group 1 (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH antagonist and then result of ART compare in two group .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist
NCT00830492
Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation
NCT01005784
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.
NCT04724343
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
NCT04108039
Antagonist/Letrozole in Poor Responders
NCT00823004
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
GnRH antagonist "ganirelix" 0.25 mg fromm 6th ovarian stimulation
ganirelix
These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
2
GnRH agonist, suprefact, stimulation with a standard long protocol
suprefact
GnRH agonist, standard protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ganirelix
These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
suprefact
GnRH agonist, standard protocol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age \< 35 years
* basal FSH \< 10 IU/L
Exclusion Criteria
* only one ovary
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yazd Research & Clinical Center for Infertility
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yazd Research & Clinical Center for Infertility
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
razieh firouzabadi, MD
Role: STUDY_CHAIR
Yazd Research & Clinical Center for Infertility
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yazd Research and Clinical Center For Infertility
Yazd, Yazd Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1387YAZDRCCI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.